KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Current Deferred Revenue (2017 - 2026)

Guardant Health's Current Deferred Revenue history spans 9 years, with the latest figure at $50.8 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue rose 43.1% to $50.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $50.8 million, a 43.1% increase, with the full-year FY2025 number at $50.8 million, up 43.1% from a year prior.
  • Current Deferred Revenue hit $50.8 million in Q4 2025 for Guardant Health, down from $56.4 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for GH hit a ceiling of $60.7 million in Q2 2025 and a floor of $7.3 million in Q3 2021.
  • Historically, Current Deferred Revenue has averaged $25.0 million across 5 years, with a median of $17.7 million in 2022.
  • Biggest five-year swings in Current Deferred Revenue: fell 29.62% in 2021 and later soared 189.29% in 2024.
  • Tracing GH's Current Deferred Revenue over 5 years: stood at $11.3 million in 2021, then soared by 53.66% to $17.4 million in 2022, then rose by 3.23% to $18.0 million in 2023, then skyrocketed by 97.43% to $35.5 million in 2024, then soared by 43.1% to $50.8 million in 2025.
  • Business Quant data shows Current Deferred Revenue for GH at $50.8 million in Q4 2025, $56.4 million in Q3 2025, and $60.7 million in Q2 2025.